Tinnitus Clinical Trial
Official title:
Evaluation of the Elimination of Tinnitus and Hyperacusis by the ØREBLUE® Method
NCT number | NCT04752176 |
Other study ID # | MAY001-PMCF001 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | March 22, 2019 |
Est. completion date | January 2023 |
Tinnitus and hyperacusis are two hearing disorders that can severely impact the patient and their quality of life, as they may induce sleeping disorders, concentration troubles, social life disturbances. Mayfair Developments has created and developed the innovating ØREBLUE® method in order to relieve, possibly completely, tinnitus and hyperacusis symptoms. The ØREBLUE® method relies on a medical device, CE marked, that consists of an auditory stimulation box associated with five softwares. This medical device diffuses thanks to a headphone a specific and personalized sound therapy treatment for the patient. This retrospective, observational study aims at collecting data about the ØREBLUE® method used in routine care and describing its efficacy on tinnitus and hyperacusis.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | January 2023 |
Est. primary completion date | March 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - Age between 18 and 85 years old - Subject seen in consultation in the investigational site from CE marking up to 2 years thereafter, - Sufficient ENT investigations, - Satisfactory general condition: non-invalidating medical history (ENT disorders and others), - The subject agrees to work on the emotional part linked to their condition, - Permanent and disabling tinnitus and/or hyperacusis, with the following characteristics for tinnitus: subjective, chronic (present for more than 1 year), resistant to usual treatments (medication, hearing aid with or without masking, psychotherapy) continued for a minimum of 6 months, severe tinnitus, disabling tinnitus (measurement with numerical scale score and THI questionnaire), - Patient informed about the study and has no objection to take part Exclusion Criteria: - Proven presence of an anxiety disorder of claustrophobia type, - History of neurological disease, in particular personal or family history of epilepsy or seizure (infantile hyperthermic convulsions, or other type of seizure), - Serious psychiatric history or attempted autolysis, concomitant use of antidepressant and neuroleptic treatment, - Bilateral cophosis, - Medication monitoring that can generate more or less tinnitus, - More than 6 months since the end of the last treatment or therapy against tinnitus, - For women: possibility of pregnancy (absence of effective contraception or certain menopause), breastfeeding woman, - Context of medico-legal litigation and / or concomitant participation in another protocol. |
Country | Name | City | State |
---|---|---|---|
France | Hearing Institute of Resources | La Rochelle |
Lead Sponsor | Collaborator |
---|---|
Mayfair Developments |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Discomfort | Discomfort level is rated on a numerical scale, from 0 to 10, where 0 means "no discomfort" and 10 means "indescribable discomfort". | From baseline through study completion, an average of 10 months. | |
Secondary | Hyperacusis Symptoms change | Hyperacusis symptoms are assessed with the Hyperacusis Handicap Inventory (HHI) questionnaire | From baseline through study completion, an average of 10 months. | |
Secondary | Hyperacusis discomfort level | Disconfort level due to hyperacusis, in Decibels, during audiometric measurements | From baseline through study completion, an average of 10 months. | |
Secondary | Tinnitus Symptoms change | Tinnitus symptoms are assessed with the Tinnitus Handicap Inventory (THI) questionnaire | From baseline through study completion, an average of 10 months. | |
Secondary | Quality of life change | Quality of life is assessed through WHODAS 2.0 questionnaire | From baseline through study completion, an average of 10 months. | |
Secondary | Sleep quality change | Sleep quality is assessed through the Pittsburgh Sleep Quality Index (PSQI) | From baseline through study completion, an average of 10 months. | |
Secondary | Depression | Depression is assessed through the Beck Depression Inventory (BPI) questionnaire | From baseline through study completion, an average of 10 months. | |
Secondary | Anxiety | Anxiety is assessed through the State-Trait Anxiety Inventory (STAI) questionnaire | From baseline through study completion, an average of 10 months. | |
Secondary | Anxiety level | Anxiety level is rated on a numerical scale, from 0 to 10, where 0 means "no anxiety" and 10 means "worst anxiety". | From baseline through study completion, an average of 10 months. | |
Secondary | Appetite level | Appetite level is rated on a numerical scale, from 0 to 10, where 0 means "no impact on appetite" and 10 means "worst impact on appetite". | From baseline through study completion, an average of 10 months. | |
Secondary | Energy level | Energy level is rated on a numerical scale, from 0 to 10, where 0 means "no impact on energy" and 10 means "worst impact on energy". | From baseline through study completion, an average of 10 months. | |
Secondary | Emotionality | Emotionality is rated on a numerical scale, from 0 to 10, where 0 means "no impact on emotionality" and 10 means "worst impact on emotionality". | From baseline through study completion, an average of 10 months. | |
Secondary | Concentration ability | Concentration ability is rated on a numerical scale, from 0 to 10, where 0 means "no impact on concentration ability" and 10 means "worst impact on concentration ability". | From baseline through study completion, an average of 10 months. | |
Secondary | Hopelessness feeling | Hopelessness feeling is rated on a numerical scale, from 0 to 10, where 0 means "no hopelessness feeling" and 10 means "worst hopelessness feeling". | From baseline through study completion, an average of 10 months. | |
Secondary | Isolation feeling | Isolation feeling is rated on a numerical scale, from 0 to 10, where 0 means "no isolation feeling" and 10 means "worst isolation feeling". | From baseline through study completion, an average of 10 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05963542 -
Efficacy of Online Acceptance and Commitment Therapy and Sound Therapy for Patients With Tinnitus and Insomnia
|
N/A | |
Recruiting |
NCT04987502 -
Virtual Reality and Subjective Tinnitus
|
N/A | |
Recruiting |
NCT04404439 -
Treatment of Tinnitus With Migraine Medications
|
Phase 4 | |
Recruiting |
NCT05533840 -
Establishment and Application of a New Imaging System for Otology Based on Ultra-high Resolution CT
|
||
Completed |
NCT03552302 -
Effects of Yoga Exercise on Participates With Tinnitus
|
||
Enrolling by invitation |
NCT02617953 -
Objective Diagnosis Method and Efficacy of Repetitive Transcranial Magnetic Stimulation as a Treatment for Tinnitus
|
N/A | |
Completed |
NCT02269839 -
A Feasibility Study Assessing the Effectiveness of rTMS in Tinnitus
|
N/A | |
Withdrawn |
NCT01663467 -
Efficacy of Internet and Smartphone Application-delivered Tinnitus Retraining Therapy
|
N/A | |
Completed |
NCT02974543 -
Somatosensory Stimulation to Alleviate Tinnitus
|
N/A | |
Completed |
NCT01929837 -
Tinnitus rTMS 2013
|
N/A | |
Completed |
NCT01927991 -
Internet-based Self-help for Tinnitus: The Role of Support
|
N/A | |
Completed |
NCT01857661 -
The Influence of the Sound Generator Combined With Conventional Amplification for Tinnitus Control: Blind Randomized Clinical Trial
|
N/A | |
Terminated |
NCT01412918 -
Inhibitor Masking Device & Sodium Channel, Voltage Gated, Type IX Alpha Subunit (SCN9) Gene Expression
|
N/A | |
Completed |
NCT01480193 -
New Therapy for Patients With Severe Tinnitus
|
N/A | |
Completed |
NCT00371436 -
Progressive Intervention Program for Tinnitus Management
|
N/A | |
Completed |
NCT00748475 -
Countering Stimulus-Induced Alpha-Desynchronization to Treat Tinnitus
|
N/A | |
Completed |
NCT00733044 -
Cost-effectiveness of Multidisciplinary Management of Tinnitus
|
N/A | |
Active, not recruiting |
NCT05518682 -
Assessment of Bimodal Stimulation Device Compliance and Satisfaction in Individuals With Tinnitus
|
N/A | |
Recruiting |
NCT05212298 -
Effects of Herbal Sleep Formula on Patients With Insomnia and Tinnitus
|
N/A | |
Completed |
NCT06025097 -
Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus.
|
Early Phase 1 |